세계 최초 상용화 기술로 심혈관 질환의 원인 분석에 혁신적 접근

Benetis Lifetime Model B Receives MFDS Approval for Precise Lesion Observation

At the ICI held in Israel, Hyung-il Kim, CEO of Dotter Inc. gave a lecture on the biodegradable stent BRS

Dotter Inc. acquired the exclusive domestic rights to EluNIR™ through a recent contract with Israeli company Medinol.
EluNIR™ is scheduled to be marketed in Korea early next year through Dotter.

심장 급사의 원인이 되는 심혈관 협착증의 예방 및 치료를 위해 스텐트(Stent)로 혈관을 넓히는 시술은 이미 일반화되었다. 하지만 기존의 금속 재질 스텐트가 체내에 장기간 자리하면서 발생할 수 있는 부작용도 지적되고 있다. 도터는 이러한 우려를 해소할 수 있는 생분해성 스텐트(Bioresorbable Stent, BRS) 솔루션을 선보였다.

[Ulsan-Newsis] Reporter Hyun-cheol Cho = Ulsan Hospital announced on January 27 that it had performed the first coronary intervention in the country to insert a more improved absorbable stent for a 50-year-old male angina patient at the Cardiocerebrovascular Center on January 20.

The Korea Health Industry Development Institute (President Deok-cheol Kwon), along with the domestic venture investment platform KDB NextRound, held the ‘2019 5th K-BIC STAR DAY’ (hereafter K-BIC Star Day) held at the IR Center of the KDB in Yeouido on the 1st. It was announced on the 2nd that it was successfully held.